In this Q&A, Andrea Valente, CEO of uMotif, discusses what it takes to build genuine trust between patients and sites, why making technology easier to use isn't the same as making patient-site ...
In today's ACT Brief, we examine why defensible trial data depends on traceability and platform ownership, what CGT site ...
In part three of her DPHARM interview, Andrea Valente, CEO of uMotif, explains why truly understanding the patient journey ...
In this episode of Beyond Compliance, Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, speaks with Cecilia Xi, PhD, VP of clinical and scientific affairs at Vivalink, ...
In part two of her DPHARM interview, Andrea Valente, CEO of uMotif, explains why the real technology challenge isn't ...
Benchmarking data showed sourcing approach did not reliably predict timeline, quality, or execution performance across 133 ...
In today's ACT Brief, we examine what patient-site relationships need most at DPHARM, how platform-based AI scales across ...
Decentralized trial models have demonstrated real gains in enrollment performance and patient access, but operational switching costs, fragmented technology stacks, and unresolved gaps in the ...
Most AI pilots in drug development fail not from poor technology but from lack of strategic prioritization, organizational readiness, integrated data infrastructure, and disciplined governance, making ...
As the life sciences industry continues to evolve, the ability to effectively manage and leverage preclinical CRO ...
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why the full ...
Most AI pilots in drug development fail not from poor technology but from lack of strategic prioritization, organizational readiness, integrated data infrastructure, and disciplined governance, making ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results